Conventional Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs) Market in China 2021
The conventional synthetic disease-modifying antirheumatic drugs (DMARDs) market in China in terms of revenue is set to grow by US$ 442 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 10.8% during the forecast period, according to data and analytics company StrategyHelix.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for conventional synthetic disease-modifying antirheumatic drugs (DMARDs). The China conventional synthetic disease-modifying antirheumatic drugs (DMARDs) market is segmented on the basis of type. By type, it is categorized into hydroxychloroquine, iguratimod, leflunomide, methotrexate, sulfasalazine, and others.
The report has profiled some of the key players of the market such as AbbVie Inc., Johnson & Johnson International Inc., Pfizer Inc., Roche Holding AG, Sanofi S.A., Shanghai Pharmaceuticals Holding Co. Ltd., Simcere Pharmaceutical Group Limited, Sunshine Guojian Pharmaceuticals (Shanghai) Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the conventional synthetic disease-modifying antirheumatic drugs (DMARDs) market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Type: hydroxychloroquine, iguratimod, leflunomide, methotrexate, sulfasalazine, and others
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China conventional synthetic disease-modifying antirheumatic drugs (DMARDs) market
Pinpoint growth sectors and trends for investment
Understand what the future of the conventional synthetic disease-modifying antirheumatic drugs (DMARDs) market in China looks like
Identify the competitive landscape and window of opportunity
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for conventional synthetic disease-modifying antirheumatic drugs (DMARDs). The China conventional synthetic disease-modifying antirheumatic drugs (DMARDs) market is segmented on the basis of type. By type, it is categorized into hydroxychloroquine, iguratimod, leflunomide, methotrexate, sulfasalazine, and others.
The report has profiled some of the key players of the market such as AbbVie Inc., Johnson & Johnson International Inc., Pfizer Inc., Roche Holding AG, Sanofi S.A., Shanghai Pharmaceuticals Holding Co. Ltd., Simcere Pharmaceutical Group Limited, Sunshine Guojian Pharmaceuticals (Shanghai) Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the conventional synthetic disease-modifying antirheumatic drugs (DMARDs) market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Type: hydroxychloroquine, iguratimod, leflunomide, methotrexate, sulfasalazine, and others
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China conventional synthetic disease-modifying antirheumatic drugs (DMARDs) market
Pinpoint growth sectors and trends for investment
Understand what the future of the conventional synthetic disease-modifying antirheumatic drugs (DMARDs) market in China looks like
Identify the competitive landscape and window of opportunity
1. MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) MARKET BY TYPE
4.1 Hydroxychloroquine
4.2 Iguratimod
4.3 Leflunomide
4.4 Methotrexate
4.5 Sulfasalazine
4.6 Others
5. COMPANY PROFILES
5.1 AbbVie Inc.
5.2 Johnson & Johnson International, Inc.
5.3 Pfizer, Inc.
5.4 Roche Holding AG
5.5 Sanofi S.A.
5.6 Shanghai Pharmaceuticals Holding Co., Ltd.
5.7 Simcere Pharmaceutical Group Limited
5.8 Sunshine Guojian Pharmaceuticals (Shanghai) Co., Ltd.
5.9 Zhejiang Hisun Pharmaceutical Co., Ltd.
6. APPENDIX
6.1 About StrategyHelix
6.2 Disclaimer
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) MARKET BY TYPE
4.1 Hydroxychloroquine
4.2 Iguratimod
4.3 Leflunomide
4.4 Methotrexate
4.5 Sulfasalazine
4.6 Others
5. COMPANY PROFILES
5.1 AbbVie Inc.
5.2 Johnson & Johnson International, Inc.
5.3 Pfizer, Inc.
5.4 Roche Holding AG
5.5 Sanofi S.A.
5.6 Shanghai Pharmaceuticals Holding Co., Ltd.
5.7 Simcere Pharmaceutical Group Limited
5.8 Sunshine Guojian Pharmaceuticals (Shanghai) Co., Ltd.
5.9 Zhejiang Hisun Pharmaceutical Co., Ltd.
6. APPENDIX
6.1 About StrategyHelix
6.2 Disclaimer
